Study: Rosiglitazone may delay progression of eye disease

A study of 124 diabetes patients showed that rosiglitazone reduced the risk of developing proliferative diabetic retinopathy or deterioration of visual acuity by curbing the formation of new blood vessels. Researchers, however, said larger studies need to be conducted before they can recommend the drug to treat the condition.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC